Origin, activation, and targeted therapy of glioma-associated macrophages

• Published in: Frontiers in immunology 2022-10, Vol.13, p.974996-974996
• Main Authors: Xu, Can, Xiao, Menglin, Li, Xiang, Xin, Lei, Song, Jia, Zhan, Qi, Wang, Changsheng, Zhang, Qisong, Yuan, Xiaoye, Tan, Yanli, Fang, Chuan
• Format: Article
• Language: English
• Subjects: Glioma; glioma associated macrophages (GAMs); Immunology; polarization; recruitment; targeted therapy; therapy resistance
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.974996

The glioma tumor microenvironment plays a crucial role in the development, occurrence, and treatment of gliomas. Glioma-associated macrophages (GAMs) are the most widely infiltrated immune cells in the tumor microenvironment (TME) and one of the major cell populations that exert immune functions. GAMs typically originate from two cell types-brain-resident microglia (BRM) and bone marrow-derived monocytes (BMDM), depending on a variety of cytokines for recruitment and activation. GAMs mainly contain two functionally and morphologically distinct activation types- classically activated M1 macrophages (antitumor/immunostimulatory) and alternatively activated M2 macrophages (protumor/immunosuppressive). GAMs have been shown to affect multiple biological functions of gliomas, including promoting tumor growth and invasion, angiogenesis, energy metabolism, and treatment resistance. Both M1 and M2 macrophages are highly plastic and can polarize or interconvert under various malignant conditions. As the relationship between GAMs and gliomas has become more apparent, GAMs have long been one of the promising targets for glioma therapy, and many studies have demonstrated the therapeutic potential of this target. Here, we review the origin and activation of GAMs in gliomas, how they regulate tumor development and response to therapies, and current glioma therapeutic strategies targeting GAMs.